Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 25 | 183 | 183 | 209 | 195 |
| Gross Profit | 25 | 183 | 183 | 209 | 195 |
| Operating Expenses | 6,262 | 9,009 | 9,024 | 11,617 | 12,637 |
| Operating Income | -6,237 | -8,826 | -8,841 | -11,408 | -12,442 |
| Other Income | 256 | 1,391 | 298 | 435 | 576 |
| Pre-tax Income | -5,981 | -7,435 | -8,543 | -10,973 | -11,866 |
| Income Tax | -3 | 2 | 4 | 20 | -7 |
| Net Income Continuous | -5,978 | -7,437 | -8,547 | -10,993 | -11,859 |
| Net Income | $-5,978 | $-7,437 | $-8,547 | $-10,993 | $-11,859 |
| EPS Basic Total Ops | -3.38 | -5.51 | -6.50 | -8.17 | -9.07 |
| EPS Basic Continuous Ops | -3.38 | -5.51 | -6.50 | -8.38 | -9.06 |
| EPS Diluted Total Ops | -3.38 | -5.51 | -6.50 | -8.17 | -9.07 |
| EPS Diluted Continuous Ops | -3.38 | -5.51 | -6.50 | -8.38 | -9.06 |
| EPS Diluted Before Non-Recurring Items | -3.38 | -5.51 | -6.00 | -8.00 | -9.00 |
| EBITDA(a) | $-6,133 | $-8,699 | $-8,713 | $-11,524 | $-12,804 |